Literature DB >> 3280153

Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

G Daugaard1, N Rossing, M Rørth.   

Abstract

To investigate the effect of high-dose cisplatin (40 mg/m2 daily for 5 days), 51Cr-EDTA clearance was used as a measure of glomerular filtration rate (GFR). 51Cr-EDTA clearance decreased significantly from 109 +/- 3 ml/min * 1.73 m2 to 68 +/- 3 ml/min * 1.73 m2 after three cycles of cisplatin and remained at this decreased level during the observation period (24 months). To determine the reliability of creatinine as a measure of GFR, we compared the simultaneous clearance of creatinine to that of 51Cr-EDTA. A good correlation between 51Cr-EDTA clearance and creatinine clearance was observed before and 3 months after termination of treatment, but no correlation was found during treatment. S-creatinine decreased significantly during treatment, probably due to muscle wasting. We conclude that s-creatinine and creatinine clearance are unsuitable measures of glomerular function during high-dose cisplatin treatment. All patients developed proteinuria during treatment. The changes in clearance ratios of beta-2-microglobulin/albumin and IgG/albumin show that the proteinuria observed during cisplatin infusion is predominantly of tubular origin, whereas the proteinuria between the treatment periods is mainly of glomerular origin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280153     DOI: 10.1007/bf00257365

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  The long-term effect of cisplatin on renal function.

Authors:  P Fjeldborg; J Sørensen; P E Helkjaer
Journal:  Cancer       Date:  1986-11-15       Impact factor: 6.860

2.  Creatinine assay by a reaction-kinetic principle.

Authors:  K Larsen
Journal:  Clin Chim Acta       Date:  1972-10       Impact factor: 3.786

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

Authors:  C L Litterst
Journal:  Toxicol Appl Pharmacol       Date:  1981-10       Impact factor: 4.219

5.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

6.  51Cr-EDTA clearance determined by one plasma sample.

Authors:  S Groth; M Aasted
Journal:  Clin Physiol       Date:  1981-08

7.  A study of the protective effect of chloride salts on cisplatin nephrotoxicity.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

8.  Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase.

Authors:  J A Kuhn; W P Argy; T A Rakowski; J K Moriarty; G E Schreiner; P S Schein
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

9.  Measurement of beta-2-microglobulin in serum and plasma by an enzyme-linked immunosorbent assay (ELISA).

Authors:  O W Bjerrum; H S Birgens
Journal:  Clin Chim Acta       Date:  1986-02-28       Impact factor: 3.786

10.  Differentiation of glomerular, tubular, and normal proteinuria: determinations of urinary excretion of beta-2-macroglobulin, albumin, and total protein.

Authors:  P A Peterson; P E Evrin; I Berggård
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

View more
  33 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

Review 5.  Renal toxicity and chemotherapy in children with cancer.

Authors:  Antonio Ruggiero; Pietro Ferrara; Giorgio Attinà; Daniela Rizzo; Riccardo Riccardi
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

6.  Measurement of glomerular function during cisplatin therapy.

Authors:  D G Waller; L Juer; J S Fleming
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

7.  Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.

Authors:  Tomoko Ogawa; Seiji Niho; Shunji Nagai; Takashi Kojima; Yoshiko Nishimura; Yuichiro Ohe; Naoki Kondo; Takuhiro Yamaguchi; Kazushi Endo; Keishiro Izumi; Hironobu Minami
Journal:  Int J Clin Oncol       Date:  2012-10-05       Impact factor: 3.402

8.  Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour.

Authors:  M Schell; P Cochat; A Hadj-Aïssa; E Bouffet; L Dubourg; M Brunat-Mentigny
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

9.  The use of the Calvert formula to determine the optimal carboplatin dosage.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.